Rockefeller Capital Management L.P. Purchases 87,372 Shares of Neurocrine Biosciences, Inc. $NBIX

Rockefeller Capital Management L.P. lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 45.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 281,320 shares of the company’s stock after purchasing an additional 87,372 shares during the period. Rockefeller Capital Management L.P. owned about 0.28% of Neurocrine Biosciences worth $39,900,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nilsine Partners LLC bought a new position in Neurocrine Biosciences in the 4th quarter worth $1,197,000. Ruffer LLP bought a new stake in Neurocrine Biosciences during the fourth quarter valued at about $2,479,000. Korea Investment CORP raised its holdings in Neurocrine Biosciences by 94.3% during the third quarter. Korea Investment CORP now owns 71,689 shares of the company’s stock valued at $10,064,000 after acquiring an additional 34,800 shares during the period. Nordea Investment Management AB lifted its position in shares of Neurocrine Biosciences by 81.3% in the fourth quarter. Nordea Investment Management AB now owns 27,202 shares of the company’s stock valued at $3,834,000 after acquiring an additional 12,195 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Neurocrine Biosciences by 17,250.0% in the third quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company’s stock valued at $1,120,000 after acquiring an additional 7,935 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on NBIX shares. Royal Bank Of Canada increased their target price on Neurocrine Biosciences from $180.00 to $183.00 and gave the stock an “outperform” rating in a research report on Friday, May 29th. Citigroup boosted their price target on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Wolfe Research initiated coverage on Neurocrine Biosciences in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 price target for the company. Zacks Research raised shares of Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 15th. Finally, Weiss Ratings upgraded shares of Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $187.52.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $158.29 on Monday. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $169.57. The stock has a market capitalization of $15.92 billion, a P/E ratio of 24.39, a PEG ratio of 1.19 and a beta of 0.39. The firm has a fifty day simple moving average of $148.53 and a two-hundred day simple moving average of $140.77.

Insider Activity

In other Neurocrine Biosciences news, insider Julie Cooke sold 36,937 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $156.22, for a total transaction of $5,770,298.14. Following the sale, the insider directly owned 22,374 shares of the company’s stock, valued at $3,495,266.28. The trade was a 62.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 2,261 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $156.71, for a total value of $354,321.31. Following the sale, the insider owned 16,225 shares in the company, valued at approximately $2,542,619.75. This trade represents a 12.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 355,234 shares of company stock worth $55,330,060. 4.60% of the stock is owned by insiders.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.